This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Innoviva, Inc.

Drug Names(s): TD-5742

Description: TD-5742 is an inhaled, long-acting muscarinic antagonist (LAMA).

Deal Structure: In March 2004, Theravance entered into a strategic alliance with GSK. Under the terms of this strategic alliance, GSK received an option to license potential new medicines from all current and future drug discovery and development programs on pre-determined terms and on an exclusive, worldwide basis. After Theravance had designated TD-5742 to be its lead LAMA compound, GSK exercised its right to license the LAMA program. Accordingly, GSK is required to fund all future development, manufacturing and commercialization activities for product candidates in this program.

Partners: GlaxoSmithKline plc

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug